¹**Integrated methylome and phenome study of the circulating proteome**

²**reveals markers pertinent to brain health**

3 Danni A Gadd¹, Robert F Hillary¹, Daniel L McCartney¹, Liu Shi², Aleks Stolicyn³, Neil Robertson⁴, 4 Rosie M Walker⁵, Robert I McGeachan⁶, Archie Campbell¹, Shen Xueyi³, Miruna C Barbu³, Claire 5 Green³, Stewart W Morris¹, Mathew A Harris³, Ellen V Backhouse⁵, Joanna M Wardlaw^{5,7,8,9}, J 6 Douglas Steele¹⁰, Diego A Oyarzún^{11,12,13}, Graciela Muniz-Terrera¹⁴, Craig Ritchie¹⁴, Alejo Nevado-7 Holgado², Tamir Chandra⁴, Caroline Hayward^{1,15}, Kathryn L Evans¹, David J Porteous¹, Simon R 8 $\text{Cox}^{16,17}$, Heather C Whalley³, Andrew M McIntosh³, Riccardo E Marioni^{1,†} ¹ Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XU 10 \degree 2 Department of Psychiatry, University of Oxford, UK, OX3 7JX ³ Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, EH10 5HF, UK
 ⁴ MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XU ⁵ Centre for Clinical Brain Sciences, Chancellor's Building, 49 Little France Crescent, Edinburgh BioQuarter, Edinburgh, EH16 4SB ⁶ Centre for Discovery Brain Sciences, University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK ⁷ Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK
 16 ⁸ Edinburgh Imaging, University of Edinburgh, Edinburgh, UK ⁹ UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK, EH8 9JZ ¹⁰ Division of Imaging Science and Technology, Medical School, University of Dundee, Dundee, UK, DD1 9SY 19 ¹¹ School of Informatics, University of Edinburgh, Edinburgh, EH8 9AB 20 $\frac{12}$ School of Biological Sciences, University of Edinburgh, Edinburgh, EH3 3JF ¹³ The Alan Turing Institute, 96 Euston Road, London, NW1 2DB ¹⁴ Centre for Clinical Brain Sciences, Edinburgh Dementia Prevention, University of Edinburgh, Edinburgh, UK, EH4 2XU ¹⁵ Medical Research Council Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XU ¹⁶ Lothian Birth Cohorts, University of Edinburgh, Edinburgh, EH8 9JZ ¹⁷ Department of Psychology, University of Edinburgh, Edinburgh, EH8 9JZ † 26^t Corresponding author: Riccardo Marioni, riccardo.marioni@ed.ac.uk

²⁷**Abstract**

28

²⁹Characterising associations between the methylome, proteome and phenome may provide insight 30 into biological pathways governing brain health. Here, we report an integrated DNA methylation and 31 phenotypic study of the circulating proteome in relation to brain health. Methylome-wide association 32 studies of 4,058 plasma proteins are performed $(N=774)$, identifying 2,928 CpG-protein associations ³³after adjustment for multiple testing. These were independent of known genetic protein quantitative 34 trait loci (pQTLs) and common lifestyle effects. Phenome-wide association studies of each protein 35 are then performed in relation to 15 neurological traits $(N=1,065)$, identifying 405 associations ³⁶between the levels of 191 proteins and cognitive scores, brain imaging measures or *APOE* e4 status. ³⁷We uncover 35 previously unreported DNA methylation signatures for 17 protein markers of brain 38 health. The epigenetic and proteomic markers we identify are pertinent to understanding and 39 stratifying brain health.

⁴⁰**Introduction**

41 The health of the ageing brain is associated with risk of neurodegenerative disease $1,2$. Relative brain 42 age – a measure of brain health calculated using multiple volumetric brain imaging measures – has 43 recently been shown to predict the development of dementia 3 . Structural brain imaging and 44 performance in cognitive tests are well-characterised markers of brain health 4 , which clearly 45 associate with potentially modifiable traits such as body mass index (BMI), smoking and diabetes $5-7$. ⁴⁶Understanding the interplay between environment, biology and brain health may therefore inform 47 preventative strategies.

⁴⁸Multiple layers of omics data indicate the biological pathways that underlie phenotypes. Proteomic ⁴⁹blood sampling can track peripheral pathways that may impact brain health, or record proteins 50 secreted from the brain into the circulatory system. Although proteome-wide characterisation of 51 cognitive decline and dementia risk $8-10$ have been facilitated at large-scale by SOMAscan[®] protein

⁶⁰Modifications to DNAm at CpG sites play differential roles in influencing gene expression at the 61 transcriptional level 13 . Additionally, DNAm accounts for inter-individual variability in circulating 62 protein levels $14-16$. Recently, through integration of DNAm and protein data, we have shown that ⁶³epigenetic scores for plasma protein levels – known as 'EpiScores' – associate with brain 64 morphology and cognitive ageing markers 17 and predict the onset of neurological diseases 18 . These 65 studies highlight that while datasets that allow for integration of proteomic, epigenetic and 66 phenotypic information are rarely-available, they hold potential to advance risk stratification. ⁶⁷Integration may also uncover candidate biological pathways that may underlie brain health.

⁶⁸Associations between protein levels and DNAm at CpGs are known as protein quantitative trait ⁶⁹methylation loci (pQTMs) and can be quantified by methylome-wide association studies (MWAS) of 70 protein levels. The largest MWAS of protein levels to date assessed 1,123 SOMAmer protein 71 measurements in the German KORA cohort $(n=944)$ ¹⁴. In that study, Zaghlool *et al* reported 98 72 pQTMs that replicated in the QMDiab cohort (n=344), with significant associations between DNAm at the immune-associated locus *NLRC5* and seven immune-related proteins (P \Box < \Box 2.5 \Box \times \Box 10⁻⁷). ⁷⁴This suggested that DNAm not only reflects variability in the proteome but is closely related to ⁷⁵chronic systemic inflammation. Hillary *et al* have also assessed epigenetic signatures for 281

⁷⁶SOMAmer protein measurements that were previously associated with Alzheimer's disease, in the 77 Generation Scotland cohort that we utilised in this study 19 . However, proteome-wide assessment of ⁷⁸pQTMs has not been tested against a comprehensive spectrum of brain health traits.

⁷⁹Here, we conduct an integrated methylome- and phenome-wide assessment of the circulating 80 proteome in relation to brain health (Fig. 1), using 4,058 protein level measurements (Supplementary 81 Table 1). We characterise CpG-protein associations (pOTMs) for these proteins in 774 individuals 82 from the Generation Scotland cohort using EPIC array DNAm at 772,619 CpG sites. We then 83 identify which of the 4,058 protein levels associate with one or more of 15 neurological traits (seven 84 structural brain imaging measures, seven cognitive scores and *APOE* e4 status) in 1,065 individuals 85 from the same cohort where the pQTM data are a nested subset. By integrating these datasets, we 86 probe the epigenetic signatures of proteins that are related to brain health. For these signatures, we 87 map potential underlying genetic components and chromatin interactions that may play a role in 88 protein level regulation. A YouTube video summarising the study and detailing access to the datasets 89 can be viewed at https://www.youtube.com/channel/UCxQrFFTIItF25YKfJTXuumQ.

⁹⁰**Results**

⁹¹**Methylome-wide studies of 4,058 plasma proteins**

92 We conducted MWAS to test for pQTM associations between 772,619 CpG sites and 4,058

93 circulating protein levels (corresponding to 4,235 SOMAmer measurements; Supplementary Table

⁹⁴1). The MWAS population included 774 individuals from Generation Scotland **(**mean age 60 years

- ⁹⁵[SD 8.8], 56% Female; Supplementary Table 2**).** 143 principal components explained 80% of the
- 96 cumulative variance in the 4,235 measurements (Supplementary Fig. 1 and Supplementary Table 3).
- ⁹⁷A threshold for multiple testing based on these components was applied across all MWAS (P <

98 $0.05/(143x772,619) = 4.5x10^{-10}$.

¹¹⁸**Pleiotropic pQTM associations in the fully-adjusted MWAS**

119 Pleiotropy was observed for both CpG sites and protein levels (Fig. 3). Nineteen proteins had 10 or

120 more pQTMs in the fully-adjusted MWAS (Supplementary Table 9). Of the 2,928 pQTMs in the

- 121 fully-adjusted MWAS, 987 involved Pappalysin-1 (PAPPA) and there were a further 1,116 pQTMs
- 122 that involved the Proteoglycan 3 Precursor (PGR3) protein. The remaining 825 pQTMs involved 189

¹³¹The pleiotropic findings for PAPPA and cg07839457 (*NLRC5* gene) replicated previous MWAS 132 results from Zaghlool *et al* ¹⁴ (944 individuals, with 1,123 protein SOMAmers). Of the 98 pQTMs 133 identified by Zaghlool *et al*, 81 were comparable (both the protein and CpG sites from the 98 pQTMs 134 were available across both MWAS). Of these 81 pQTMs, 26 replicated at our significance threshold 135 $(P < 4.5x10^{-10})$ with the same direction of effect, a further 16 replicated at the epigenome-wide 136 significance threshold $(P < 3.6x10^{-8})^{26}$ and a further 39 replicated at nominal $P < 0.05$ 137 (Supplementary Table 11 and Supplementary Fig. 3). When accounting for 26 pQTMs that were 138 previously reported by Zaghlool et al and 10 pQTMs that were previously reported by Hillary et al 139 14,19 , 2,892 of the 2,928 fully-adjusted pQTMs were novel. Of these 2,892 novel pQTMs, 1,109 140 involved the levels of 41 proteins that were measured by Zaghlool et al (973 pQTMs for PAPPA and 141 136 additional pQTMs for the levels of 40 proteins), whereas 1,783 pQTMs involved the levels of 142 proteins that were previously unmeasured (1,116 pQTMs for PRG3 and 667 further pQTMs for 148 143 proteins).

¹⁴⁴**Proteome associations with brain health phenotypes**

¹⁴⁵We next conducted a proteome-wide association study of brain health characteristics (protein 146 PheWAS of brain imaging, cognitive scoring and *APOE* e4 status, alongside age and sex; Fig. 4).

¹⁴⁷Distribution plots for the seven cognitive scores and seven brain imaging phenotypes are presented in ¹⁴⁸Supplementary Figs. 4-5. A maximum sample of 1,065 individuals was available **(**mean age 59.9 149 years [SD 9.6], 59% Female; Supplementary Table 2); all 774 individuals from the pQTM study ¹⁵⁰were included in these analyses. A threshold for multiple testing adjustment was calculated based on 151 143 independent components that explained >80% of the 4,235 SOMAmer levels (Supplementary 152 Table 3 and Supplementary Fig. 1). This equated to $P < 0.05/(143) = 3.5 \times 10^{-4}$. The levels of 587 153 plasma proteins were associated with age and 545 were associated with sex, with 222 proteins ¹⁵⁴common to both phenotypes **(**Supplementary Table 12**)**. When comparable associations from three 155 studies (with N>1000) were tested ^{20,27,28}, 97% of age and 98% of sex associations replicated in one 156 or more of studies (Supplementary Table 12). 157 There were 191 unique protein markers that had a total of 405 associations with brain health 158 characteristics (Supplementary Fig. 6 and Fig. 4a). These consisted of 95 brain imaging ¹⁵⁹(Supplementary Table 13), 296 cognitive test score (Supplementary Table 14) and 14 *APOE* e4 160 status (Supplementary Table 15) associations. Supplementary Table 16 stratifies these associations 161 by direction of effect and Supplementary Table 17 provides full summary statistics for all 405 162 associations. Of the seven brain morphology traits, Relative Brain Age and General Fractional 163 Anisotropy (gFA) had the largest number of associations, with 24 and 22 protein markers identified, ¹⁶⁴respectively. Of the cognitive score traits, Processing Speed and General Cognitive Ability scores 165 were associated with the highest number of protein markers (102 and 73, respectively). The 14 ¹⁶⁶*APOE* e4 status associations are plotted in Supplementary Fig. 7. 167 Stratifying the 405 associations by direction of effect revealed that the majority (89%) of 168 associations indicated that higher levels of the proteins were associated with less favourable brain 169 health (Supplementary Table 16). Eighty-seven of the 405 associations involved protein leves that

170 were associated with more favourable brain health; this signature included the levels of SLITRK1,

77 September 2007

171 NCAN and COL11A2. Higher levels of ASB9, RBL2, HEXB and SMPD1 associated with poorer 172 brain health. Protein interaction network analyses for the genes corresponding to the 191 protein 173 markers (Supplementary Fig. 8) indicated that many of the proteins in these signatures clustered 174 together, implying shared underlying functions. An inflammatory cluster including CRP, ITIH4, C3, ¹⁷⁵C5, COL11A2 and SIGLEC2 was present and higher levels of these markers were associated with 176 poorer brain health outcomes. Gene set enrichment analyses on the 191 genes corresponding to the 177 protein markers (Supplementary Fig. 9) supported the link between many of the proteins associated 178 with poorer brain health and the innate immune system, while also implicating extracellular matrix, ¹⁷⁹lysosomal, metabolic and additional inflammatory pathways. Tissue expression profiles of the 191 ¹⁸⁰genes (Supplementary Fig. 10**)** indicated that many of the markers were expressed non-neurological 181 tissues; however, some proteins were expressed in nervous tissues. Markers such as ASB9 and 182 NCAN were found to be consistently identified across multiple brain imaging traits as markers of 183 poorer and better brain health, respectively (Supplementary Table 16). While many of the 184 associations for brain imaging measures identified proteins that were distinct from those found for 185 cognitive scores and *APOE* e4 status, 22 protein markers were associated with both a cognitive score 186 and a brain imaging trait (Fig. 4b and Supplementary Table 18). Of these 22 proteins, there were 10 187 principal components that had a cumulative variance of $>80\%$ and five components had eigenvalues ¹⁸⁸> 1 (Supplementary Fig. 11). Three *APOE* e4 status markers (ING4, APOB and CRP) were also 189 associated with cognitive scores (Fig. 4b).

¹⁹⁰**Replication of protein PheWAS associations**

191 Six of the 14 *APOE* e4 status associations replicated previous SOMAmer protein findings (N

192 SOMAmers = 4,785 and N participants = 227)¹⁰, and eight novel relationships involved NEFL, ING4,

193 PAF, MENT, TMCC3, CRP, FAM20A and PEF1. Several of the markers for cognitive function

194 were identified in previous work relating Olink proteins to cognitive function (such as CPM) 29 and

195 work that characterised SOMAmer signatures of cognitive decline and incident Alzheimer's disease 196 (such as SVEP1)⁸. No studies have performed SOMAmer-based, whole proteome PheWAS studies 197 of the brain imaging and cognitive score traits we have profiled in a heathy ageing population that ¹⁹⁸were not enriched for neurodegenerative diseases. However, replication of associations from several studies $9,29,30$ was found for a small subset of associations (Supplementary Table 19).

²⁰⁰**Integration of the brain health proteome with our pQTM dataset**

201 Differential DNAm signatures were explored for the 191 protein markers that had $P < 3.5x10^{-4}$ in ²⁰²associations with either cognitive scores, brain imaging measures or *APOE* e4 status in the protein 203 PheWAS. Of the 191 proteins, 17 had pQTMs in the fully-adjusted MWAS. Higher levels of 15 of 204 these proteins were associated with poorer brain health, while AMY2A and CST5 were associated 205 with more favourable brain health. There were a total of 35 pQTMs involving 31 unique CpGs that ²⁰⁶were located within 20 distinct genes (Supplementary Table 20), with 15 *trans* (Fig. 5) and 20 *cis* 207 associations. All pQTMs were previously unreported. The 20 *cis* pQTMs involved the levels of ²⁰⁸CHI3L1, IL18R1, SIGLEC5, OLFM2, UGDH, CRHBP, AMY2A and CFHR1 proteins. The *trans* 209 pQTMs involved the levels of SCUBE1, RBL2, TNFRSF1B, CST5, HEXB, ACY1, CRTAM, 210 SMPD1 and RBP5 proteins.

211 Of the 20 cis pQTMs, 11 involved CpGs in different genes to the protein-coding gene on the same 212 chromosome, whereas the remaining 9 pQTMs involved CpGs located within the protein-coding ²¹³gene. Several CpG sites were associated with multiple protein levels in the *trans* pQTMs (Fig. 5). ²¹⁴DNAm at site cg06690548 in the *SLC7A11* gene was associated with RBP5, ACY1 and SCUBE1 215 levels. The cg11294350 site in the *CHPT1* gene was associated with HEXB and SMPD1 levels. The 216 cg07839457 site in the NLRC5 gene was associated with the levels of CRTAM and TNFRSF1B. ²¹⁷There was also a protein that had several *trans* associations with multiple CpG sites; pQTMs were

en de la provincia de la provi

218 identified between circulating RBL2 levels and cg01132052, cg0539861, cg18487916, cg27294008 ²¹⁹and cg18404041, within the *NEK4/ITIH3/ITIH1* gene region of chromosome 3.

²²⁰**Functional mapping of neurological pQTMs**

- 221 A lookup that integrated information from the GoDMC and eQTLGen databases assessed whether
- ²²²pQTMs were partially driven by an underlying genetic component. This identified methylation
- 223 quantitative trait loci (mOTLs) for CpGs that were associated with CHI3L1, IL18R1 and SIGLEC5
- 224 and were also expression quantitative trait loci ($eQTLs$) for the respective protein levels
- ²²⁵(Supplementary Table 20). Further visual inspection of the distributions for the 35 pQTMs indicated
- 226 that trimodal distributions suggestive of unaccounted SNP effects were present for $CpGs$
- 227 involved in seven of the pQTMs (Supplementary Fig. 12).
- ²²⁸Tissue expression profiles for the 33 genes that were linked to either CpGs or proteins in the 35

229 neurological pQTMs are summarised in Supplementary Fig. 13. Gene set enrichment for these 33

230 genes identified enrichment for immune effector pathways in a subset of 11 genes, whereas a cluster

- 231 of four genes (SMPD1, HEXB, AMY2A and AMY2B) were enriched for amylase and hydrolase
- 232 activity (Supplementary Fig. 14).
- 233 Of the 35 pOTMs, seven had CpGs that were located in either a CpG Shore or Shelf position and

234 there were 13 that were located either 1500 bp or 200 bp from the TSS of the protein-coding gene

- 235 (Supplementary Table 20). Fifteen pQTMs involved CpGs that were located in the gene body and 7
- 236 were located in either the first exon or UTR regions (Supplementary Table 20).
- 237 Promoter-capture Hi-C and ChIP-sequencing integration was used to assess the interactions and
- 238 chromatin states of our pQTMs and associated CpG loci. This analysis focused on 11 of the 20 *cis*
- 239 pQTMs that involved CpGs on the same chromosome as the protein-coding gene, but were located in
- 240 a different gene. Mapping information is presented for the seven proteins involved in these pQTMs

²⁵¹**Discussion**

²⁵²We have conducted a large-scale integration of the circulating proteome with indicators of brain 253 health and blood-based DNA methylation. We characterised 191 protein markers that were 254 associated with either brain imaging measures, cognitive scores or *APOE* e4 status in an ageing 255 population. We also report methylome-wide characterisations for the SOMAscan[®] panel V.4 (4,058) 256 protein measurements) in a nested subset of this population. By integrating these datasets, we 257 uncovered 35 methylation signatures for 17 protein markers of brain health. We delineated pQTM ²⁵⁸CpGs that had evidence of underlying genetic influence and characterised the potential for chromatin 259 interactions for genes involved in *cis* pQTMs. As this population consists of older individuals that ²⁶⁰were not enriched for neurodegenerative diseases, the markers we identify are likely indicators of 261 healthy brain ageing.

²⁶²Many of the 191 proteins identified in the protein PheWAS were part of inflammatory clusters with 263 shared functions in acute phase response, complement cascade activity, innate immune activity and 264 cytokine pathways. Tissue expression analyses suggested that a large proportion of the 191 protein

265 markers were not expressed in the brain; this supports work suggesting that sustained peripheral 266 inflammation influences general brain health 3132 and accelerates cognitive decline $8,33-35$. However, a 267 subset of proteins were expressed in the central nervous system. Given that leakage at the blood-268 brain-barrier interface has been hallmarked as a part of healthy brain ageing $36,37$, there is a 269 possibility that brain-derived proteins may enter the bloodstream as biomarkers. SLIT and NTRK 270 Like Family Member 1 (SLITRK1), Neurocan (NCAN) and IgLON family member 5 (IGLON5) 271 were examples of proteins expressed in brain for which higher levels associated with either larger 272 grey matter volume, larger whole brain volume, or higher general fractional anisotropy. SLITRK1 273 localises at excitatory synapses and regulates synapse formation in hippocampal neurons 38 . 274 Neurocan (NCAN) is a component of neuronal extracellular matrix and is linked to neurite growth 39 . ²⁷⁵IGLON5 has been implicated in maintenance of blood-brain-barrier integrity and an anti-IGLON5 276 antibody disease involves the deterioration of cognitive health 40 . Taken together, the protein markers 277 identified in the PheWAS may, therefore, reflect pathways that could be targeted to improve brain 278 health.

279 Integration of our fully-adjusted protein MWAS dataset revealed 35 associations between DNAm 280 and 17 protein markers of brain health (Fig. 6; Supplementary Table 20). All 35 associations were 281 novel. While this study is focused on blood $DNAm -$ limiting generalisation to brain $DNAm -$ many 282 of the 35 pQTMs involved CpGs and proteins that have been previously implicated in neurological 283 processes. DNAm at site cg06690548 (located in the *SLC7A11* gene) was of particular interest; ²⁸⁴differential DNAm at this CpG in blood has been identified as a causal candidate for Parkinson's 285 disease (N > 900 cases and N > 900 controls)⁴¹. Xc- is the cystine-glutamate antiporter encoded by ²⁸⁶*SLC7A11*, which facilitates glutamatergic transmission, oxidative stress defence and microglial 287 response in the brain 4243 and is a target for the neurodegeneration-associated environmental 288 neurotoxin β-methylamino-L-alanine 41 . Analyses in the wider Generation Scotland cohort suggests 289 that cg06690548 is a site associated with alcohol consumption 44 . The proteins associated with

 290 cg06690548 in the subset of this cohort we assessed (ACY1, SCUBE1 and RBP5) have known links 291 to liver function $45-47$. DNAm at cg06690548 in blood has also been recently implicated in the largest 292 MWAS of amyotrophic lateral sclerosis (ALS) to date $(6,763 \text{ cases}, 2,943 \text{ controls})^{48}$. Given that 293 ACY1, SCUBE1 and RBP5 were markers for either lower processing speed and higher relative brain 294 age, the CpG sites we identify in this study – such as $c\mu$ = 06690548 – may be important plasma 295 markers for mediation of environmental risk on brain health that merit further exploration. 296 cg06690548 lies within the first intron of *SLC7A11*⁴¹, indicating that this site is of potential 297 functional significance.

²⁹⁸The presence of *NLRC5* and various other inflammatory proteins in our neurological protein pQTMs 299 suggests that the methylome may capture an inflammatory component of brain health. Many of the 300 genes corresponding to CpGs and proteins involved in the 35 pQTMs were enriched for immune 301 effector processes and were not expressed in brain. However, some markers did show evidence for ³⁰²brain-specific expression, such as acid sphingomyelinase (SMPD1) and Hexosaminidase Subunit 303 Beta (HEXB). The HEXB and SMPD1 proteins associated with DNAm at cg11294350 (in the ³⁰⁴*CHPT1* gene), are involved in neuronal lipid degradation in the brain and have been associated with the onset of a range of neurodegenerative conditions $49-52$. RBL2 is another protein that had partial 306 expression signals across brain regions; the *NEK4/ITIH3/ITIH1* region was the location for five ³⁰⁷CpGs with differential DNAm linked to RBL2 levels. This region is implicated in schizophrenia and 308 bipolar disorder by several large-scale, genome-wide association studies (GWAS) $53-56$. Similarly, 309 the *RBL2* locus has been associated with intelligence, cognitive function and educational attainment 310 in GWAS (n > 260,000 individuals) $33,57,58$.

311 Given that this study utilised CpGs from the Illumina EPIC array, 15 of the 31 unique CpGs did not 312 have mQTL characterisations in public databases, which primarily comprise results from the earlier 313 450K array. However, our plots showing pQTM associations suggested that for several CpGs (such

314 as cg11294350 that associated with SMPD1 and HEXB), there may be a partial genetic component 315 influencing DNAm. As mQTLs tend to explain 15-17% of the additive genetic variance of DNAm 59 , 316 it is possible that the signals we isolate in these instances are partially driven by genetic loci, but are 317 also likely driven by unmeasured environmental and biological influences. In the case of SIGLEC5, 318 IL18R1 and CHI3L, mQTLs were identified that were also eQTLs, providing evidence that mQTLs 319 for these CpG sites were possible regulators of protein expression.

320 Integration of promoter-capture Hi-C chromatin interaction and ChIP-seq databases ⁶⁰ provided 321 evidence for long-range interaction relationships for *cis* pQTMs with CpGs in different gene regions 322 that are proximal to the protein-coding gene of interest. This suggests that in such instances, the 323 pQTMs may reflect regulatory relationships in the 3-dimensional genomic neighbourhood. The ³²⁴pQTMs therefore direct us towards pathways that can be tested in experimental constructs. Positional 325 information suggested that many CpGs involved in neurological pQTMs lay within 1500 bp of the ³²⁶TSS of the respective protein-coding gene. While positional information of CpGs is thought to infer 327 whether DNAm is likely to play a role in the expression regulation of nearby genes, this is still 328 somewhat disputed. Some studies suggest that transcription factors regulate DNAm 61 and 329 differential methylation at gene body locations predicts dosage of functional genes 62 . Additionally, 330 the DNAm signatures of proteins we quantify represent widespread differences across blood cells 331 that are related to circulating protein levels and are therefore not derived from the same cell-types as 332 proteins. Despite this limitation, previous work supports DNAm scores for proteins as useful markers 333 of brain health, suggesting there is merit in integrating DNAm signatures of protein levels in disease 334 stratification 18 .

³³⁵Our study has several limitations. First, though full replication of our results was not possible, our 336 replication of pQTMs identified by Zaghlool *et al* 14 reinforces inflammation signalling as intrinsic to 337 the methylome signature of blood proteins. This also suggests that pQTMs may be common across

338 ancestries. Second, we observed a substantial inflation for PAPPA and PRG3 proteins. While 339 comprehensive adjustment for estimated immune cells was performed and the remainder of CpGs 340 involved in pQTMs did not show high correlations (Supplementary Fig. 2), concurrently measured ³⁴¹blood components such as haemoglobin, red blood cells and platelets were not available. Future ³⁴²studies should seek to resolve signals with more detailed blood-cell phenotyping and immune cell 343 estimates 63 . Third, 89% of the proteins identified in our protein PheWAS did not have epigenetic 344 pQTMs; this may be due to 1) the presence of pathways relating to neurological disease that are not 345 reflected by blood immune cell DNAm, 2) underpowered analyses, or 3) the presence of indirect 346 associations that are not captured by our MWAS approach. Fourth, the extent of non-specific and 347 cross-aptamer binding with SOMAmer technology has not been fully resolved 64 . Fifth, there are 348 likely unknown genetic influences on pQTMs. Further characterisation of pQTLs and advances in 349 multi-omic modelling techniques 15 will aid in the separation of genetic and environmental 350 influences on epigenetic signatures. Sixth, differences in blood and brain DNAm and pQTLs are 351 emerging; these indicate that blood-based markers may not fully align to biology of brain 352 degeneration $65,66$. However, our ChIP-seq analysis of chromatin regulation suggested that some 353 regulatory states may persist between blood and brain. Seventh, profiling DNAm signatures alone 354 cannot capture the full role of the epigenome in brain health. Integration of more diverse epigenetic ³⁵⁵markers will be critical to further resolve these relationships. Finally, though we have incorporated a 356 wide portfolio of brain health measures, we recognise that these are not extensive. Increasing 357 triangulation across modalities, as we have shown here, will be useful in identifying candidate 358 markers.

In conclusion, by integrating epigenetic and proteomic data with cognitive scoring, brain morphology and *APOE* e4 status, we identify 191 protein markers of brain health. We characterise DNAm signatures for all 4,058 proteins included in the study, uncovering 35 associations between 362 differential DNAm and the levels of 17 of the protein markers of brain health outcomes. These data

³⁶³identify candidate targets for the preservation of brain health and may inform risk stratification 364 approaches.

³⁶⁵**Methods**

³⁶⁶**The Generation Scotland sample population**

367 The Stratifying Resilience and Depression Longitudinally (STRADL) cohort used in this study is a 368 subset of $N=1,188$ individuals from Generation Scotland: The Scottish Family Health Study (GS). 369 Generation Scotland constitutes a large, family-structured, population-based cohort of $>24,000$ 370 individuals from Scotland 67 . Individuals were recruited to GS between 2006 and 2011. During a 371 clinical visit detailed health, cognitive, and lifestyle information was collected in addition to 372 biological samples. Of the 21,525 individuals contacted for participation, $N=1,188$ completed 373 additional health assessments and biological sampling approximately five years after GS baseline 68 . 374 Of these, N=1,065 individuals had proteomic data available and N=778 of these had DNAm data 375 available. Supplementary Table 2 summarises the demographic characteristics across the two 376 groups, with descriptive statistics for phenotypes.

³⁷⁷**Proteomic measurement**

378 SOMAscan[®] V.4 technology was used to quantify plasma protein levels. This aptamer-based assay 379 facilitates the simultaneous measurements of multiple SOMAmers (Slow Off-rate Modified 380. Aptamers) 69 . SOMAmers were processed for 1,065 individuals from the STRADL subset of GS. 381 Briefly, binding between plasma samples and target SOMAmers was achieved during incubation and 382 quantification was recorded using a fluorescent signal on microarrays. Quality control steps included 383 hybridization normalization, signal calibration and median signal normalization to control for inter-384 plate variation. Full details of quality control stages are provided in Supplementary Methods. In the 385 final dataset, 4,235 SOMAmer epitope measures were available in 1,065 individuals and these

386 corresponded to 4,058 unique proteins (classified by common Entrez gene names). Supplementary 387 Table 2 provides annotation information for the 4,235 SOMAme measurements that were available.

³⁸⁸**DNAm measurement**

³⁸⁹Measurements of blood DNAm in the STRADL subset of GS subset were processed in two sets on 390 the Illumina EPIC array using the same methodology as those collected in the wider Generation Scotland cohort. Quality control details have been reported previously $70-72$ and further details are 392 provided in Supplementary Methods. Briefly, samples were removed if there was a mismatch 393 between DNAm-predicted and genotype-based sex and all non-specific CpG and SNP probes (with 394 allele frequency $> 5\%$) were removed from the methylation file. Probes which had a beadcount of 395 less than 3 in more than 5% of samples and/or probes in which $>1\%$ of samples had a detection 396 P>0.01 were excluded. After quality control, 793,706 and 773,860 CpG were available in sets 1 and ³⁹⁷2, respectively. These sets were truncated to include a total of 772,619 common probes and were 398 joined together for use in the MWAS, with 476 individuals included in set 1 and 298 individuals in 399 set 2. DNAm-specific technical variables (measurement batch and set) were adjusted in all MWAS 400 and PheWAS models.

⁴⁰¹**Phenotypes in Generation Scotland**

⁴⁰²All phenotypes in Generation Scotland MWAS and PheWAS samples are summarised in 403 Supplementary Table 2. An epigenetic score for smoking exposure, EpiSmokEr 73 was calculated 404 for all individuals with DNAm. The meffil 74 implementation of the Houseman method was used to 405 calculate estimated white blood cell (WBC) proportions for Sets 1 and 2. Blood reference panels 406 were sourced from Reinius et al 75 . The 'blood gse35069 complete' panel was used to imputed neasures for Monocytes, Natural Killer cells, Bcells, Granulocytes, CD4⁺T cells and CD8⁺T cells. ⁴⁰⁸Eosinophil and Neutrophil estimates were also sourced through the 'blood gse35069' panel. Body 409 mass index (body weight in kilograms, divided by squared height in metres) was available for all

410 individuals, alongside depression status (defined using a research version of the Structured Clinical 411 Interview for DSM disorders (SCID) assessment), which was coded as a binary variable of no ⁴¹²history of depression (0) or lifetime episode of depression (1). Five individuals did not have 413 depression status information and were excluded from MWAS and PheWAS analyses, where ⁴¹⁴appropriate. *APOE* e4 status was available for 1,050 individuals. *APOE* e4 status was coded as a 415 numeric variable (e2e2 = 0, e2e3 = 0, e3e3 = 1, e3e4 = 2, e4e4 = 2). Fifteen e2e4 individuals were 416 excluded due to small sample size.

417 Scores from five cognitive tests (Supplementary Fig. 4; Supplementary Table 2) measured at the 418 clinic visit for the STRADL subset of GS were considered. Full details for the specific scores has 419 been detailed previously 68 and further details can be found in Supplementary Methods. Briefly, 420 these included the Wechsler Logical Memory Test (maximum possible score of 50), the Wechsler 421 Digit Symbol Substitution Test (maximum possible score of 133), the verbal fluency test (based on 422 the Controlled Oral Word Association task), the Mill Hill Vocabulary test (maximum possible score 423 of 44) and the Matrix Reasoning test (maximum possible score of 15). Outliers were defined as ⁴²⁴scores >3.5 standard deviations above or below the mean and were removed prior to analysis. The 425 first unrotated principal component combining logical memory, verbal fluency, vocabulary and digit 426 symbol tests was calculated as a measure of general cognitive ability $({}^{6}g)$. General fluid cognitive ⁴²⁷ability ('gf') was extracted using the same approach, but with the vocabulary test (a crystallised 428 measure of intelligence) excluded from the model. While highly similar to g, the gf score is 429 exclusive to measures such as memory and processing capability that are considered fluid. gf may 430 therefore be of greater relevance for assessing cognitive decline in ageing individuals.

431 The derived brain volume measures (Supplementary Fig. 5; Supplementary Table 2) were recorded 432 at two sites (Aberdeen and Edinburgh) 68 . Brain volume data included total brain volume (ventricle 433 volumes excluded), global grey matter volume, white matter hyperintensity volume and total

434 intracranial volume. Intracranial volume was treated as a covariate to adjust for head size in all tests 435 including brain volume associations. The derived global white matter integrity measures included 436 global fractional anisotropy (gFA) and global mean diffusivity (gMD). The protocols applied to 437 derive the brain volume measures from T1-weighted scans, and white matter integrity measures from 438 diffusion tensor imaging (DTI) scans have been previously described $35,68,76$ and additional details are 439 also provided in Supplementary Methods. Brain Age was estimated using the software package 440 'brainageR' (Version 2.1; DOI: 10.5281/zenodo.3476365, available at https://github.com/james-441 cole/brainageR), which uses machine learning and a large training set to predict age from whole-442 brain voxel-wise volumetric data derived from structural T1 images 3 . This estimate was regressed 443 on chronological age to produce a measure of Relative Brain Age (residuals from the linear model). ⁴⁴⁴Outliers for all imaging variables were defined as measurements >3.5 standard deviations above or 445 below the mean and were removed prior to analysis.

⁴⁴⁶**Phenome-wide association analyses**

447 Prior to running protein PheWAS analyses, protein levels were transformed by rank-based inverse 448 normalisation and scaled to have a mean of zero and standard deviation of 1. Models were run using 449 the lmekin function in the coxme R package 77 . This modelling strategy allows for mixed-effects 450 linear model structure with adjustment for relatedness between individuals. Models were run in the 451 maximum sample of 1,095 individuals, with the 4,235 protein levels as dependent variables and 452 phenotypes as independent variables. A random intercept was fitted for each individual and a kinship 453 matrix was included as a random effect to adjust for relatedness. Age, sex (male $= 1$, reference 454 female = 0), numerical *APOE* e4 status variable (e2 = 0, e3 = 1, e4 = 2), cognitive and brain imaging 455 phenotypes were included as scaled predictors. Continuous variables were scaled to mean of zero 456 and variance one. Diagnosis of depression (case $= 1$, reference control $= 0$) at the STRADL clinic 457 visit in GS was included as a covariate in all models, due to known selection bias for depression

461 Three regression models were considered. For the analyses with age and sex as the predictors of 462 interest, two coefficients (β 1 and β 2) were extracted.

463 Protein level ~ Intercept + β 1 age + β 2 sex + depression + study site + lag group + (1|individual) + 464 (1|kinship)

⁴⁶⁵For the analyses with one of cognitive scoring, *APOE* e4 status or non-volumetric brain imaging as 466 the predictor of interest, the β 3 coefficient was extracted.

467 Protein level ~ Intercept + age + sex + β 3 phenotype + depression + study site + lag group + 468 $(l|individual) + (1|kinship)$

469 Finally, for the models with volumetric brain imaging measures as the predictor of interest the β 4 470 coefficient was extracted.

471 Protein level ~ Intercept + age + sex + β 4 phenotype + depression + study site*ICV + lag group + 472 edited + batch + (1|individual) + (1|kinship)

⁴⁷³All analyses of brain volume measures included adjustment for intracranial volume and study site as ⁴⁷⁴main effects, in addition to the interaction between these variables. ICV was used to account for head 475 size. Imaging data processing batch, and presence or absence of manual intervention during quality 476 control (edited) variables were also included as covariates, wherever appropriate.

⁴⁷⁷P-values for all PheWAS models were calculated in R using effect size estimates (beta) and standard 478 errors (SE) as follows: pchisq((beta/SE)^2, 1, lower.tail=F). The Prcomp package ⁷⁸ was used to 479 generate principal components for the 4,235 SOMAmer measurements ($N=1,065$). 143 components

480 explained $>80\%$ of the cumulative variance in protein levels (Supplementary Fig. 1 and 481 Supplementary Table 3); these components were used to derive the PheWAS multiple testing 482 adjustment threshold of P < 0.05 / 143 = $3.5x10^{-4}$. This method was chosen due to the presence of 483 high intercorrelations within the protein data.

⁴⁸⁴**Epigenome-wide association study of protein levels**

485 Prior to running the MWAS, protein levels for 774 individuals with complete phenotypic information 486 were log transformed and regressed on age, sex, study site, lag group and 20 genetic principal 487 components (generated from multidimensional scaling of genotype data from the Illumina 610-488 Quadv1 array). Residuals from these models were then rank-based inverse normalised and taken 489 forward as protein level data. Methylation data were in M-value format and were pre-adjusted for 490 age, sex, processing batch, methylation set, depression status 73 and known pQTL effects (from a ⁴⁹¹previous genome-wide association study of 4,034 SOMAmers targeting 3,622 proteins from Sun *et* 492 *al*) 24 in the basic MWAS. A second model further adjusted for estimated white blood cell 493 proportions (Monocytes, CD4⁺T cells, CD8⁺T cells, BCells, Natural Killer cells, Granulocytes and ⁴⁹⁴Eosinophils). While Neutrophil estimates were available, they were excluded due to high correlation ⁴⁹⁵(>95%) with Granulocyte proportions **(**Supplementary Fig. 22**)**. Finally, the fully-adjusted model 496 further regressed DNAm onto an epigenetic score for smoking, EpiSmokEr⁷³ and body mass index 497 (BMI).

498 Omics-data-based complex trait analysis (OSCA)⁷⁹ Version 0.41 was used to run EWAS analyses. 499 Within OSCA, a genetic relationship matrix (GRM) was constructed for the STRADL population. A 500 threshold of 0.05 was used to identify 120 individuals likely to be related based on their genetic 501 similarity. For this reason, the MOA method was used to calculate associations between individual ⁵⁰²CpG sites and protein levels, with the addition of the GRM as a random effect to adjust for

503 relatedness between individuals ⁷⁹. CpG sites were the dependent variables and the 4,235 proteins 504 were the independent variables.

505 Five fully-adjusted models did not converge (NAGLU, CFHR2, DAP, MST1, PILRA) and were 506 excluded. A threshold for multiple testing correction ($P < 4.5x10^{-10}$) was based on 143 independent 507 protein components with cumulative variance $>80\%$ (Supplementary Fig. 1 and Supplementary 508 Table 3) $(P < 0.05/(143x772.619)$ CpGs). A more conservative threshold based on total number of 509 SOMAmers was also considered $(P < 0.05/(4,235x772,619) = 1.5x10^{-11})$ and is detailed in 510 Supplementary Tables 4-6. pQTMs were classified as *cis* if the CpG was on the same chromosome 511 as the protein-coding gene and fell within 10Mb of the transcriptional start site (TSS) of the protein 512 gene. pQTMs involving a CpG located on a different chromosome to the protein-coding gene, or 513 >10Mb from the TSS of the protein gene were classed as *trans*.

514 Circos plots were created with the circlize package (Version 0.4.12) 80 . BioRender.com was used to 515 create Figs. 1, 2, 3 and 6. All analyses were performed in R (Version 4.0) 81 .

⁵¹⁶**Functional mapping and tissue expression analyses**

517 Functional mapping and annotation (FUMA) 82 gene set enrichment analyses were conducted for 518 genes corresponding to protein markers that were identified through the PheWAS study, in addition 519 to genes linked to either CpGs or proteins in the neurological pQTM subset. Protein-coding genes 520 were selected as the background set and ensemble v92 was used with a false discovery rate (FDR) 521 adjusted $P < 0.05$ threshold for gene set testing. For the genes corresponding to protein markers in 522 the PheWAS a minimum overlapping number of genes was set to 3, whereas this was set to 2 for the 523 genes involved in neurological pQTMs for the purposes of visualisation. The STRING 83 database ⁵²⁴was queried to build a protein interaction network based on all proteins that had associations in the 525 PheWAS. mQTL and eQTL lookups were performed using the GoDMC 59 and eQTLGen databases

526 $\frac{84}{7}$, respectively. UCSC database searches were used to profile the positional information relating to 527 CpGs in the pQTMs involving proteins associated with brain health.

⁵²⁸Although inter-chromosomal chromatin interactions are unlikely to be stable and persistent, seven 529 proteins with *cis* pQTMs involving CpGs located intra-chromosomally to the proximal protein-530 coding gene were considered for ChIP-seq and promoter-capture Hi-C mapping to interrogate local 531 chromatin interactions and states that might form the basis for co-regulation of these loci. ChIP-seq 532 data from peripheral blood mononuclear cells (PBMCs) and brain hippocampus were selected from the ENCODE project 86 , with accession identifiers available in Supplementary Table 21. Processed 534 promoter-capture Hi-C data for brain hippocampal tissue was integrated from Jung et al, 60 and is 535 available at NCBI Geo with accession GSE86189. Data concerning both promoter-prometer 536 interactions and promoter-other interactions were concatenated and all regions subsequently 537 visualised on the WashU epigenome browser 87 .

⁵³⁸**Ethics declarations**

539 All components of GS received ethical approval from the NHS Tayside Committee on Medical 540 Research Ethics (REC Reference Number: 05/S1401/89). GS has also been granted Research Tissue 541 Bank status by the East of Scotland Research Ethics Service (REC Reference Number: 20/ES/0021), 542 providing generic ethical approval for a wide range of uses within medical research.

⁵⁴³**Data availability**

544 Datasets generated in this study are made available in Supplementary Tables. Source data are 545 provided with this paper.

546 Fully-adjusted MWAS summary statistics for protein levels are available through Zenodo [insert]

547 details once accepted files are uploaded] and hosted on the MRC-IEU EWAS catalog [insert details

548 once accepted files are uploaded] 25 .

- ⁵⁴⁹A YouTube video summarising the findings of the study and detailing how to access files can be
- 550 viewed at https://www.youtube.com/channel/UCxQrFFTIItF25YKfJTXuumQ.
- 551 The source datasets from the cohorts that were analysed during the current study are not publicly
- 552 available due to them containing information that could compromise participant consent and
- 553 confidentiality. Data can be obtained from the data owners. Instructions for accessing Generation
- 554 Scotland data can be found here: https://www.ed.ac.uk/generation-scotland/for-researchers/access;
- 555 the 'GS Access Request Form' can be downloaded from this site. Completed request forms must be
- 556 sent to access@generationscotland.org to be approved by the Generation Scotland Access
- 557 Committee.

⁵⁵⁸**Code availability**

559 All R code used in this study is available with open access at the following Gitlab repository:

⁵⁶⁰https://gitlab.com/dannigadd/epigenome-and-phenome-wide-study-of-brain-health-outcomes/-

561 $/\text{tree/main}$

⁵⁶²**Acknowledgements**

⁵⁶³**This research was funded in whole, or in part, by the Wellcome Trust [104036/Z/14/Z,** ⁵⁶⁴**108890/Z/15/Z, 221890/Z/20/Z]. For the purpose of open access, the author has applied a CC** ⁵⁶⁵**BY public copyright licence to any Author Accepted Manuscript version arising from this** ⁵⁶⁶**submission.** D.A.G. and R.F.H. are supported by funding from the Wellcome Trust 4-year PhD in ⁵⁶⁷Translational Neuroscience–training the next generation of basic neuroscientists to embrace clinical 568 research [108890/Z/15/Z]. R.I.M is supported by funding from the Wellcome Trust PhD for 569 clinicians, Edinburgh Clinical Academic Track for Veterinary Surgeons. D.L.Mc.C. and R.E.M. are 570 supported by Alzheimer's Research UK major project grant ARUK-PG2017B−10. R.E.M is 571 supported by Alzheimer's Society major project grant AS-PG-19b-010. Generation Scotland

572 received core support from the Chief Scientist Office of the Scottish Government Health Directorates ⁵⁷³(CZD/16/6) and the Scottish Funding Council (HR03006). Genotyping and DNA methylation 574 profiling of the GS samples was carried out by the Genetics Core Laboratory at the Clinical Research 575 Facility, University of Edinburgh, Scotland and was funded by the Medical Research Council UK 576 and the Wellcome Trust (Wellcome Trust Strategic Award "STratifying Resilience and Depression ⁵⁷⁷Longitudinally" ([STRADL; Reference 104036/Z/14/Z]). Proteomic analyses in STRADL were 578 supported by Dementias Platform UK (DPUK). DPUK funded this work through core grant support 579 from the Medical Research Council [MR/L023784/2]. C.H. is supported by an MRC University Unit 580 Programme Grant MC UU 00007/10 (OTL in Health and Disease). L.S. is funded by DPUK 581 through MRC (grant no. MR/L023784/2) and the UK Medical Research Council Award to the 582 University of Oxford (grant no. MC_PC_17215). L.S. also received support from the NIHR 583 Biomedical Research Centre at Oxford Health NHS Foundation Trust.

⁵⁸⁴S.R.C is supported by the Medical Research Council (MR/R024065/1), a National Institutes of 585 Health research grant (R01AG054628) and a Sir Henry Dale Fellowship jointly funded by the 586 Wellcome Trust and the Royal Society (Grant Number 221890/Z/20/Z).

587 JDS is funded by MRC grants MR/S010351/1, MR/W002566/1 and MR/W002388/1. JMW is 588 supported by the UK Dementia Research Institute which receives its funding from DRI Ltd, funded 589 by the UK Medical Research Council, Alzheimer's Society and Alzheimer's Research UK. EB is 590 supported by Stroke Association/BHF/Alzheimer's Society 'Rates Risks and Routes to Reduce 591 Vascular Dementia' (R4VaD) Priority Programme Award in Vascular Dementia (16 VAD 07).

592 The authors acknowledge the work of Rebecca Madden, Marco Squillace and Laura Klinkhamer 593 who aided in the quality control of volumetric brain imaging data.

⁵⁹⁴**Author contributions**

- 595 D.A.G., and R.E.M., were responsible for the conception and design of the study. D.A.G. carried out
- 596 the data analyses. D.A.G., and R.E.M., drafted the article. S.R.C., and H.W., advised on
- 597 methodology. R.F.H., and D.L.Mc., contributed to methodology and data analyses. R.I.McG., S.M.,
- ⁵⁹⁸R.M.W., L.S., D.L.Mc., R.M.W., A.C., A.N.H., C.H., K.L.E., D.J.P., H.W., A.M.M., and S.R.C.,
- 599 contributed to data methylation and proteomic data collection and preparation. A.S., M.C.B.,
- ⁶⁰⁰M.A.H., E.V.B., J.D.S., S.X., C.G., and J.M.W processed the brain imaging data. D.A.O., G.M.T.,
- ⁶⁰¹and C.R., provided scientific counsel. T.C., and N.R., consulted on chromatin analyses. R.E.M.,
- ⁶⁰²supervised the project. All authors read and approved the final manuscript.

⁶⁰³**Competing interests**

- ⁶⁰⁴R.E.M has received a speaker fee from Illumina and is an advisor to the Epigenetic Clock
- ⁶⁰⁵Development Foundation. A.M.M has previously received speaker's fees from Illumina and Janssen
- 606 and research grant funding from The Sackler Trust. R.F.H. has received consultant fees from
- 607 Illumina. All other authors declare no competing interest.

⁶⁰⁸**Materials and correspondence**

- ⁶⁰⁹All correspondence and material requests should be sent to Dr Riccardo Marioni at
- 610 riccardo.marioni@ed.ac.uk.

References

- 1. Ly, M. *et al.* Late-life depression and increased risk of dementia: a longitudinal cohort study.
- *Transl. Psychiatry 2021 111* **¹¹**, 1–10 (2021).
- 2. Shi, Y. & Wardlaw, J. M. Update on cerebral small vessel disease: a dynamic whole-brain
- disease. *Stroke Vasc. Neurol.* **¹**, 83–92 (2016).
- 3. Biondo, F. *et al.* Brain-age predicts subsequent dementia in memory clinic patients. *medRxiv* 2021.04.03.21254781 (2021) doi:10.1101/2021.04.03.21254781.
- 4. Cox, S. R., Ritchie, S. J., Fawns-Ritchie, C., Tucker-Drob, E. M. & Deary, I. J. Structural
- brain imaging correlates of general intelligence in UK Biobank. *Intelligence* **⁷⁶**, 101376 (2019).
- 5. Corley, J. *et al.* Epigenetic signatures of smoking associate with cognitive function, brain structure, and mental and physical health outcomes in the Lothian Birth Cohort 1936. *Transl. Psychiatry* **⁹**, (2019).
- 6. Stillman, C. M., Weinstein, A. M., Marsland, A. L., Gianaros, P. J. & Erickson, K. I. Body– 625 Brain Connections: The Effects of Obesity and Behavioral Interventions on Neurocognitive Aging. *Front. Aging Neurosci.* **⁹**, 115 (2017).
- 7. Livingston, G. *et al.* Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *The Lancet* vol. 396 413–446 (2020).
- 8. Lindbohm, J. V *et al.* Association of plasma proteins with rate of cognitive decline and dementia: 20-year follow-up of the Whitehall II and ARIC cohort studies. *medRxiv* 2020.11.18.20234070 (2020) doi:10.1101/2020.11.18.20234070.
- 9. Walker, K. A. *et al.* Large-scale plasma proteomic analysis identifies proteins and pathways

- 20. Sun, B. B. *et al.* Genomic atlas of the human plasma proteome. *Nature* **⁵⁵⁸**, 73–79 (2018).
- 21. Houseman, E. A. *et al.* DNA methylation arrays as surrogate measures of cell mixture
- 657 distribution. *BMC Bioinformatics* **13**, 86 (2012).
- 22. McCartney, D. L. *et al.* Epigenetic signatures of starting and stopping smoking. *EBioMedicine* **37**, 214–220 (2018).
- 23. McCartney, D. L. *et al.* Epigenetic prediction of complex traits and death. *Genome Biol.* **¹⁹**, 661 136 (2018).
- 24. Sun, B. B. *et al.* Genomic atlas of the human plasma proteome. *Nature* **⁵⁵⁸**, 73–79 (2018).
- 25. MRC-IEU. The MRC-IEU catalog of epigenome-wide association studies. Avaialable at: http://www.ewascatalog.org. Accessed April 2021. (2021).
- 26. Saffari, A. *et al.* Estimation of a significance threshold for epigenome-wide association studies. **42**, 22–23 (2017).
- 27. Ferkingstad, E. *et al.* Large-scale integration of the plasma proteome with genetics and disease. *Nat. Genet. 2021 5312* **⁵³**, 1712–1721 (2021).
- 28. Lehallier, B. *et al.* Undulating changes in human plasma proteome profiles across the lifespan. *Nat. Med.* **²⁵**, 1843–1850 (2019).
- 29. Harris, S. E. *et al.* Neurology-related protein biomarkers are associated with cognitive ability and brain volume in older age. *Nat. Commun.* **¹¹**, 1–12 (2020).
- 30. Shi, L. *et al.* Identification of plasma proteins relating to brain neurodegeneration and vascular
- pathology in cognitively normal individuals. *Alzheimer's Dement. Diagnosis, Assess. Dis.*

- 58. Savage, J. E. *et al.* Genome-wide association meta-analysis in 269,867 individuals identifies
- 739 new genetic and functional links to intelligence. *Nat. Genet.* **50**, 912–919 (2018).
- 59. Min, J. L. *et al.* Genomic and phenotypic insights from an atlas of genetic effects on DNA
- methylation. *Nat. Genet.* **⁵³**, 1311–1321 (2021).
- 60. Jung, I. *et al.* A Compendium of Promoter-Centered Long-Range Chromatin Interactionsin the 743 Human Genome. *Nat. Genet.* **51**, 1442 (2019).
- 61. Héberlé, É. & Bardet, A. F. Sensitivity of transcription factors to DNA methylation. *Essays Biochem.* **⁶³**, 727 (2019).
- 62. Arechederra, M. *et al.* Hypermethylation of gene body CpG islands predicts high dosage of

functional oncogenes in liver cancer. *Nat. Commun. 2018 91* **⁹**, 1–16 (2018).

- 63. Salas, L. A. *et al.* Enhanced cell deconvolution of peripheral blood using DNA methylation for high-resolution immune profiling. *Nat. Commun. 2022 131* **¹³**, 1–13 (2022).
- 64. Pietzner, M. *et al.* Genetic architecture of host proteins involved in SARS-CoV-2 infection. *Nat. Commun.* **¹¹**, 6397 (2020).
- 65. Yang, C. *et al.* Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. *Nat. Neurosci. 2021 249* **²⁴**, 1302–1312 (2021).
- 66. Braun, P. R. *et al.* Genome-wide DNA methylation comparison between live human brain and peripheral tissues within individuals. *Transl. Psychiatry 2019 91* **⁹**, 1–10 (2019).
- 67. Smith, B. H. *et al.* Cohort profile: Generation scotland: Scottish family health study (GS:
- 757 SFHS). The study, its participants and their potential for genetic research on health and illness.
- *Int. J. Epidemiol.* **⁴²**, 689–700 (2013).

- 77. Therneau, T. M. coxme: Mixed Effects Cox Models. R package version 2.2-16.
- 782 https://CRAN.R-project.org/package=coxme. Accessed April 2021. (2020).
- 783 78. prcomp function RDocumentation.
- 784 https://www.rdocumentation.org/packages/stats/versions/3.6.2/topics/prcomp.
- 79. Zhang, F. *et al.* OSCA: A tool for omic-data-based complex trait analysis. *Genome Biol.* **²⁰**, (2019).
- 80. Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. circlize implements and enhances circular visualization in R. *Bioinformatics* **³⁰**, 2811–2812 (2014).
- 81. (2017), R. C. T. R: A language and environment for statistical computing. R Foundation for 790 Statistical Computing, Vienna, Austria.
- 82. Watanabe, K., Taskesen, E., Van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nat. Commun. 2017 81* **⁸**, 1–11 (2017).
- 83. Szklarczyk, D. *et al.* The STRING database in 2021: customizable protein–protein networks,
- and functional characterization of user-uploaded gene/measurement sets. *Nucleic Acids Res.*
- **49**, D605–D612 (2021).
- 84. Võsa, U. *et al.* Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. *Nat. Genet. 2021 539* **⁵³**, 1300–1310 798 (2021).
- 85. Kent, W. *et al.* UCSC Genome Browser: The human genome browser at UCSC. *Genome Res.* **12**, 996–1006 (2002).

86. Sloan, C. A. *et al.* ENCODE data at the ENCODE portal. *Nucleic Acids Res.* **⁴⁴**, D726–D732

and the state of th

- 802 (2016).
- 803 87. Li, D., Hsu, S., Purushotham, D., Sears, R. L. & Wang, T. WashU Epigenome Browser update
- ⁸⁰⁴2019. *Nucleic Acids Res.* **⁴⁷**, W158–W165 (2019).

805

806

⁸⁰⁷**Figure legends**

⁸⁰⁸**Figure 1. Integrated methylome and phenome study of the plasma proteome in relation to** ⁸⁰⁹**brain health.** Study design and key results are presented in this flow diagram. 1,065 individuals 810 from Generation Scotland had the levels of 4,058 plasma proteins (corresponding to 4,235 811 SOMAmers) measured. A methylome-wide association study (MWAS) of the 4,058 plasma protein 812 levels was conducted in 774 individuals that represented a nested subset of the full sample with ⁸¹³DNAm measurements available. This identified 2,928 CpG-protein (pQTM) associations. A 814 phenome-wide protein association study (Protein PheWAS) identified 191 protein levels that were 815 associated with a minimum of one brain health trait ($N>=909$). Integration of the protein MWAS and 816 PheWAS results identified 35 pQTMs that involved the levels of 17 protein markers of brain health 817 and 31 unique CpGs located in 20 genes.

⁸¹⁸**Figure 2. Methylome-wide studies of 4,058 plasma proteins. a** Summary of MWAS results for 4,058 protein levels in Generation Scotland (N=774). MWAS pQTMs that had $P < 4.5x10^{-10}$ in the ⁸²⁰basic, white blood cell proportion (WBC)-adjusted and fully-adjusted models. *Cis* associations ⁸²¹(purple) and *trans* associations (green) are summarised for each model. Covariates used to adjust 822 DNAm are described for each model. Protein levels were adjusted for age, sex, 20 genetic principal ⁸²³components (PCs) and technical variables and normalised prior to running MWAS. **b** Flow diagram 824 showing the distinction between the highly pleiotropic PAPPA and PRG3 protein pQTMs and the 825 825 pQTMs that involved the levels of a further 189 proteins. **c** Genomic locations for 825 of the 826 2,928 fully-adjusted pQTMs, excluding highly pleotropic associations for PAPPA and PRG3 protein 827 levels. Chromosomal location of CpG sites (x-axis) and protein genes (y-axis) are presented. The 434 828 *cis* pQTMs (purple) lay on the same chromosome and $\leq 10Mb$ from the transcriptional start site ⁸²⁹(TSS) of the protein gene, whereas the 391 *trans* pQTMs (green) lay > 10Mb from the TSS of the

830 protein gene or on a different chromosome. A list of the full association counts for each protein and 831 CpG site can be found in Supplementary Tables 8-9.

Figure 3. Pleiotropic associations in the fully-adjusted MWAS. a pQTMs that had $P < 4.5x10^{-10}$ 833 in the fully-adjusted MWAS are plotted as individual points with chromosomal locations of the 191 834 protein genes (upper) and the 1,837 CpGs (lower) on the x-axis. 19 proteins with ≥ 10 associations 835 with CpGs are highlighted in turquoise and labelled on the upper plot. Nine CpGs with ≥ 6 836 associations with protein levels are highlighted in turquoise on the lower plot. **b** Summary of genes 837 with highly pleiotropic CpG signals in the fully-adjusted MWAS. The fully-adjusted MWAS pQTMs 838 can be accessed in Supplementary Table 6. A list of the full association counts for each protein and 839 CpG site can be found in Supplementary Tables 8-9. ⁸⁴⁰**Figure 4. PheWAS of 4,058 plasma proteins and brain health. a** Number of protein marker 841 associations with $P < 3.5x10^{-4}$ for each of the 15 traits related to brain health in the phenome-wide 842 protein association studies (protein PheWAS). These studies included a maximum sample of 1,065 843 individuals with protein measurements from Generation Scotland and tested for associations between 844 15 phenotypes and the levels of 4,058 plasma proteins. Cognitive score (turquoise), brain imaging ⁸⁴⁵(light blue) and *APOE* e4 status (dark blue) associations are summarised. **b** Heatmap of standardised 846 beta coefficients for 77 of the 405 protein PheWAS associations ($P < 3.5x10^{-4}$) indicated by an 847 asterisk. They include three proteins that had associations with both *APOE* e4 status and one or more 848 cognitive scores, in addition to 22 proteins that had associations with both a brain imaging measure 849 and a cognitive score. Negative and positive beta coefficients are shown in blue and red, 850 respectively. A heatmap describing the full 405 associations for *APOE* e4 status, cognitive scores 851 and brain imaging measures is available in Supplementary Fig. 6. Full summary statistics for the 405 852 associations are presented in Supplementary Table 17 and the subset of 77 associations shown in part 853 b can be accessed in Supplementary Table 18.

⁸⁵⁴**Figure 5. pQTMs involving protein markers of brain health.** Circular plot showing 15 *trans* 855 pQTM associations between DNAm at 11 CpG sites and the levels of nine proteins that were 856 associated with one of more of the neurological phenotypes ($P < 3.5x10^{-4}$). Chromosomal positions 857 are given on the outermost circle. Full details of the 35 pQTMs, including 20 *cis* associations are 858 reported in Supplementary Table 20.

⁸⁵⁹**Figure 6. Integration of candidate marker associations. a** Three *trans* associations with the CpG 860 site cg06690548 in the *SLC7A11* gene, which encodes a synaptic protein that is linked to 861 environmental mediation in Parkinson's disease and is involved in glutamate transmission and 862 oxidative stress. **b** Five *trans* associations between CpGs in the *ITIH3/ITIH1/NEK4* region on 863 chromosome 3 and the levels of RBL2, which was associated with reductions in Global Grey Matter ⁸⁶⁴Volume. **c** Two *trans* associations between DNAm at cg11294350 in the *CHPT1* gene and two 865 proteins with lysosomal-associated function (SMPD1 and HEXB) that were associated with higher ⁸⁶⁶Relative Brain Age and lower General Fractional Anisotropy. Associations with a positive beta 867 coefficient are denoted as red connecting lines, whereas associations with a negative beta coefficient ⁸⁶⁸are denoted as blue connecting lines. The full 15 *trans* associations and 20 *cis* associations can be 869 found in Supplementary Table 20.

Protein levels adjusted for: Age, Sex, pQTLs, technical covariates, 20 genetic PCs Association threshold: $P < 4.5x10^{-10}$

N=774 individuals, N=4,058 protein levels (4,235 SOMAmer measurements)

b

